S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
The single greatest medical breakthrough of all time? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
The single greatest medical breakthrough of all time? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
66,000% upside on tiny biotech? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Forecast, Price & News

$2.86
+0.08 (+2.88%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.73
$2.88
50-Day Range
$2.34
$3.55
52-Week Range
$2.25
$11.02
Volume
431,079 shs
Average Volume
878,113 shs
Market Capitalization
$207.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Kezar Life Sciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
506.1% Upside
$17.33 Price Target
Short Interest
Healthy
4.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.94mentions of Kezar Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.31) to ($1.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

103rd out of 983 stocks

Pharmaceutical Preparations Industry

40th out of 486 stocks


KZR stock logo

About Kezar Life Sciences (NASDAQ:KZR) Stock

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
Kezar Life Sciences (NASDAQ:KZR) PT Lowered to $19.00
“Amazon Loophole” could hand you $28,544 in “royalty” payouts
Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.
8-K: Kezar Life Sciences, Inc.
Kezar Life Sciences GAAP EPS of -$0.31
KZR Kezar Life Sciences, Inc.
Wells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)
See More Headlines

KZR Price History

KZR Company Calendar

Last Earnings
3/14/2023
Today
6/03/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+506.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-68,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.49 per share

Miscellaneous

Free Float
66,759,000
Market Cap
$207.09 million
Optionable
Not Optionable
Beta
0.16

Key Executives

  • John Fowler
    Chief Executive Officer & Director
  • Marc L. BelskyMarc L. Belsky
    Chief Financial Officer & Secretary
  • Noreen Roth Henig
    Chief Medical Officer
  • Pattie Chiang
    Vice President & Controller
  • Andrea Fan
    Vice President-Biology













KZR Stock - Frequently Asked Questions

Should I buy or sell Kezar Life Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares.
View KZR analyst ratings
or view top-rated stocks.

What is Kezar Life Sciences' stock price forecast for 2023?

3 brokers have issued twelve-month price targets for Kezar Life Sciences' stock. Their KZR share price forecasts range from $13.00 to $20.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 506.1% from the stock's current price.
View analysts price targets for KZR
or view top-rated stocks among Wall Street analysts.

How have KZR shares performed in 2023?

Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR stock has decreased by 59.4% and is now trading at $2.86.
View the best growth stocks for 2023 here
.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,940,000 shares, a decrease of 14.8% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 2.9 days.
View Kezar Life Sciences' Short Interest
.

When is Kezar Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our KZR earnings forecast
.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its earnings results on Tuesday, March, 14th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01.

What ETFs hold Kezar Life Sciences' stock?

ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.52%), BlackRock Inc. (6.16%), State Street Corp (4.47%), Sphera Funds Management LTD. (2.61%), Hood River Capital Management LLC (1.98%) and Granahan Investment Management LLC (1.55%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment.
View institutional ownership trends
.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $2.86.

How much money does Kezar Life Sciences make?

Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $207.09 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com.

This page (NASDAQ:KZR) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -